Designing herpes viruses as oncolytics

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation       | Peters, Cole, and Samuel D Rabkin. 2015. “Designing herpes viruses as oncolytics.” Molecular Therapy Oncolytics 2 (1): 15010. doi:10.1038/mto.2015.10. http://dx.doi.org/10.1038/mto.2015.10. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Published Version | doi:10.1038/mto.2015.10                                                                                                                                                                          |
| Citable link    | http://nrs.harvard.edu/urn-3:HUL.InstRepos:26860140                                                                                                                                               |
| Terms of Use    | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
Designing herpes viruses as oncolytics

Cole Peters1,2 and Samuel D Rabkin1,2

Oncolytic herpes simplex virus (oHSV) was one of the first genetically-engineered oncolytic viruses. Because HSV is a natural human pathogen that can cause serious disease, it is incumbent that it can be genetically-engineered or significantly attenuated for safety. Here, we present a detailed explanation of the functions of HSV-1 genes frequently mutated to endow oncolytic activity. These genes are nonessential for growth in tissue culture cells but are important for growth in postmitotic cells, interfering with intrinsic antiviral and innate immune responses or causing pathology, functions dispensable for replication in cancer cells. Understanding the function of these genes leads to informed creation of new oHSVs with better therapeutic efficacy. Virus infection and replication can also be directed to cancer cells through tumor-selective receptor binding and transcriptional- or post-transcriptional miRNA-targeting, respectively. In addition to the direct effects of oHSV on infected cancer cells and tumors, oHSV can be “armed” with transgenes that are: reporters, to track virus replication and spread; cytotoxic, to kill uninfected tumor cells; immune modulatory, to stimulate antitumor immunity; or tumor microenvironment altering, to enhance virus spread or to inhibit tumor growth. In addition to HSV-1, other alphaherpesviruses are also discussed for their oncolytic activity.

Molecular Therapy — Oncolytics (2015) 2, 15010; doi:10.1038/mto.2015.10; published online 22 July 2015

Today there are many therapies to address the malady of cancer, although often with incomplete success. A confounding issue with conventional therapies is that they do not specifically target tumor cells, often destroying the normal untransformed cells of the patient in the process of treatment. Chemotherapeutics and radiation generally disrupt and kill any cell that is rapidly synthesizing DNA, tumor or not. Surgery removes tissues that appear to be tumors and often leaves behind malignant cells. These therapies lack the targeted and continual killing of tumor cells which oncolytic virus therapy offers. Oncolytic viruses (OV) selectively replicate in and kill tumor cells while sparing normal cells.1 Oncolytic activity is endowed through multiple mechanisms: viruses with a natural selectivity for tumor cells (i.e., myxoma and Newcastle disease viruses), vaccine vectors that have been genetically manipulated or attenuated (i.e., measles and vaccinia viruses), and genetically-engineered viruses with mutations in pathogenic genes, genes required for replication in normal cells, and/or retargeted to tumor cell receptors (i.e., adenovirus and herpes simplex virus (HSV)). Infecting a tumor with an OV leads to a positive feedback system, whereby an OV infects a tumor cell and produces more therapeutic virus to infect and kill more tumor cells, thereby spreading throughout the tumor while sparing normal tissues. OVVs have advantages over chemotherapy, antibody, and radiation therapies because they are biological agents capable of renewing themselves whilst spreading throughout the tumor.

Most viruses are very small 10–200 nm particles and all reproduce their genetic material during infection of a host cell. A virus is unable to replicate by itself and thus hijacks the host’s transcriptional and translational machinery in order to create more virions before exiting and/or killing the host cell. Tumors are made up of dividing cells with diminished control of normal cell cycle/cell death and biosynthesis regulation, allowing them to endlessly proliferate. The increased levels of DNA and protein synthesis required for dividing tumor cells, compared to normal nondividing cells, makes them more permissive for productive viral replication.

The HSV-1 virion is composed of an envelope, a tegument, and a viral capsid core. The envelope is studded with viral glycoproteins responsible for grasping host attachment factors heparin sulfate, nectin-1, PILRα, and herpesvirus entry mediator (HVEM), and inducing membrane fusion.2 The tegument is made up of multiple HSV-1 proteins, including ICP0, ICP4, and Us11, which are freed into the cytosol to prepare the cell for virus replication.2 The capsid is transported to the cell’s nucleus where viral replication will begin. HSV-1’s lytic lifecycle is composed of three sequential steps. First, α or immediate early (IE) genes are transcribed into mRNAs and translated. The five IE proteins (ICP0, ICP4, ICP22, ICP27, and ICP47) are responsible for gene regulation, disabling certain innate and adaptive immune functions, as well as enabling the virus to move to the next step in its lifecycle.2 Once the IE ICP4 protein is recruited to the virus genome, β or Early genes (E) are transcribed. Many of the E genes are involved in the replication of the virus’s DNA genome. Discrete compartments form in the nucleus of infected cells where viral DNA replication occurs. The final step in the virus lifecycle is the Late (L) step, whereby the L or γ genes are transcribed and translated after viral DNA synthesis. The new viral genomes are packaged...
Gene Mutations in HSV-1 Endowing Oncolytic Activity

The HSV-1 genome has many genes that can be deleted or mutated to confer safety and/or tumor targeting specificity (Figure 1). In this section, we will discuss the function of genes mutated in oHSV, what roles they play in the replication cycle of the virus, and how mutations in these genes confer oncolytic activity. The genetic alterations of oHSVs are described in Table 1. The parenthesized letters (E, I, L) indicate when the gene is expressed during the HSV-1 lifecycle. The key distinction to be made when designing an oHSV is: what is the difference between the tumor cells to be destroyed and the normal cells to be spared?

Nucleotide Metabolism

One general feature of cancer cells that distinguishes them from the majority of normal cells, which are postmitotic, is that they proliferate, and thus maintain sufficient nucleotide pools for DNA replication. HSV-1 harbors several genes involved in nucleotide metabolism (thymidine kinase, ribonucleotide reductase, uracil DNA glycosylase) that permit virus replication in nondividing cells lacking sufficient nucleotide pools. Mutations in these genes confer specificity for dividing cells and often attenuate viral pathogenicity as well.

Thymidine kinase/UL23 (E)

HSV-1 thymidine kinase (TK) is a multifunctional enzyme that catalyzes the creation of deoxythymidine 5'-phosphate (dTMP) from deoxycytidine, as well as phosphorylating deoxycytidine and nucleoside analogs, creating precursors for viral DNA synthesis. Loss of TK activity halts HSV-1 replication in nondividing cells, making TK mutants safer than wild type HSV-1. However, the antiviral drug acyclovir, ganciclovir, and foscarnet are active against HSV mutants lacking TK activity. These drugs inhibit the viral DNA polymerase, DNA glycosylase, and TK, respectively, by competing with nucleotides for entry into the cell. HSV TK mutants are unable to replicate in the face of these drugs.

ICP6/UL39 (E)

ICP6 is the large subunit of the viral ribonucleotide reductase, which transforms ribonucleotides into deoxyribonucleotides (dNMP) by reducing the 2'-COH group. HSV-1 requires an abundant supply of dNMPs to synthesize new viral genomes. ICP6 is essential for HSV replication in noncycling cells, making ICP6-null oHSVs selective for dividing cells. Mutating ICP6 in oHSV restricts the virus to cycling cells, thus giving the virus a greater ability to replicate in tumor cells, increasing cellular ribonucleotide reductase activity, through the use of ENT1 inhibitors, or 5FU or Fludarabine, which increase the replication of ICP6 of HSV-1.14,15 For example, an approximate 30% increase in ribonucleotide reductase activity after ENT1 inhibition with dilazep resulted in a greater than 10-fold increase in virus yield.14 Mutating ICP6 in oHSV restricts the virus to cycling cells, thus giving the virus a greater ability to replicate in tumor cells. Likewise, mutations within the ICP6 gene also prevent HSV from harming normal tissue.

ICP6, through its N-terminus directly binds eIF4E, expediting the formation of the eIF4 protein translation complex via eIF4E phosphorylation, and stabilizes interactions between eIF4G and eIF4E. However, the N-terminal domain alone, as in hrR3, does not promote complex formation. ElF4 complex formation is often

Figure 1  Schematic map of herpes simplex virus (HSV) genome illustrating the position of genes (IE, E, L) deleted or mutated in oHSVs. The genome consists of unique long (L) and short (S) sequences bracketed by terminal (TR) and internal (IR) inverted repeat sequences and separated by the joint region. The number of a sequence repeats is variable. Arrows indicate direction of transcription.
| Oncolytic virus | HSV gene mutations (deletion: Δ; inactivating mutation: -) | Transgenes | Reference |
|----------------|----------------------------------------------------------|------------|-----------|
| 1716*          | γ34.5Δ                                                   | ICP6-LacZ fusion in ICP6 | 182       |
| 1716-6         | γ34.5Δ, ICP6-                                           | ICP6-LacZ fusion in ICP6 | 23        |
| 3616UB         | UNG (UL2)-, γ34.5Δ                                      | UNG-LacZ fusion in UNG | 27        |
| C134           | γ34.5Δ                                                  | CMVpro-CMV IRS1 | 52        |
| Δ68H-6         | γ34.5 BBDΔ, ICP6-                                       | ICP6-LacZ fusion in ICP6 | 23        |
| ΔPK            | HSV-2; ICP10-PKΔ                                        | ICP6-LacZ fusion in ICP6 | 96        |
| DI/8.36tk      | TK-                                                     | LacZ       | 7         |
| Di5ptk         | TKΔ                                                     | ICP6-LacZ fusion in ICP6 | 6         |
| FusOn-H2       | HSV-2; ICP10-PKΔ                                        | CMVpro-eGFP-ICP10 RR fusion | 97       |
| G207*          | γ34.5Δ, ICP6-                                           | ICP6-LacZ fusion in ICP6 | 22        |
| G47Δ*          | γ34.5Δ, ICP6-, ICP47Δ, ICP47pro-Us11                    | ICP6-LacZ fusion in ICP6 | 55        |
| G47ΔUs11fluc   | γ34.5Δ, ICP6-, ICP47Δ, ICP47pro-Us11                    | Us11pro-fluc, ICP6pro-LacZ in ICP6 | 183       |
| HF10*          | IRLΔ, UL56-LATΔ, gB39, UL53-55 duplicated               | ICP6-LacZ fusion in ICP6 | 85        |
| hrR3           | ICP6-                                                   | ICP6-LacZ fusion in ICP6 | 25        |
| JDOG           | ICP0Δ, Joint deletion (1 copy of ICP4, γ34.5)           | CMVpro-eGFP in ICP0 | 83        |
| KM100          | ICP0γ247Δ, VP16γ1314                                     | ICP6-LacZ fusion in ICP6 | 88        |
| KM110          | ICP0γ247Δ, VP16γ222                                      | ICP6-LacZ fusion in ICP6 | 88        |
| L1BR1          | HSV-2; Us3Δ                                             | ICP8pro-LacZ in Us3 | 77        |
| MG18L          | Us3Δ, ICP6-                                             | ICP6-LacZ fusion in ICP6 | 24        |
| NV1020* (R7020) | UL24A, UL5, 6 (duplicated), TKΔ, UL56Δ, Joint deletion (1 copy of ICP0, ICP4, γ34.5) | ICP4pro-TK, HSV-2: gG, PK, in joint | 87        |
| NV1023         | UL24+, UL5, 6 (duplicated), TK+, UL56Δ, Joint deletion (1 copy of ICP0, ICP4, γ34.5), ICP47Δ, Us11Δ, Us10Δ | ICP47pro-LacZ | 87        |
| NV1066         | Joint deletion (1 copy of ICP0, ICP4, γ34.5) copy, TKΔ | CMVpro-GFP in Joint, BAC in TK | 184       |
| R3616          | γ34.5Δ                                                  | ICP6-LacZ fusion in ICP6 | 42        |
| R7041          | Us3Δ                                                    | ICP6-LacZ fusion in ICP6 | 69        |
| SUP1           | γ34.5Δ, ICP47Δ, ICP47pro-Us11                           | γ34.5pro-Gluc | 57        |

**Targeted vectors**

| bM24-TE        | ICP4Δ, US3-, ICP6-                                      | 4F2 enh-TRE-CMVminpro-ICP4, ICP6-LacZ fusion in ICP6 | 107       |
| CMV-ICP4-143T (-145T) (amplicon plasmid) | CgalΔ3 (ICP4Δ) helper HSV | miR 143 or 145 targeting sequence in ICP4 | 106       |
| D12.CALP       | ICP4Δ, TK-, UL24Δ, US3-                                 | TKpro-LacZ, 4F2 enh-Calponin pro-ICP4 in TK | 108       |
| G92A           | ICP4Δ, TK-, UL24Δ, US3-                                 | TKpro-LacZ, Albumin enh-pro-ICP4 in TK | 90        |
| KeM34.5        | γ34.5Δ, ICP6-                                           | Msi pro-γ34.5 in ICP6 | 118       |
| KGE4:T124      | Deletion of residues 2-24 and amino acid substitution, Y38C, in gD, gB:NT | αhuEGFR scFv in gD2-24Δ, gC-GFP fusion, miR-124 target in ICP43' UTR | 120       |
| KNC            | Deletion of residues 2-24 and amino acid substitution, Y38C, in gD, gB:NT | αhuCEA scFv inserted in gD2-24Δ | 127       |
| KNE            | Deletion of residues 2-24 and amino acid substitution, Y38C, in gD, gB:NT | αEGFRscFv inserted in gD2-24Δ | 127       |
| LCSOV          | gHΔ                                                    | ApoE-AATpro-gH-miR112a, miR124a, miRlet7 targets in gH | 121       |
| Myb34.5        | ICP6Δ, γ34.5Δ                                          | Myb pro-γ34.5 in ICP6 | 113       |
| oHSV-MDK-34.5  | γ34.5Δ, ICP6Δ                                          | Mdk pro-γ34.5 and ICP6-GFP fusion in ICP6 | 119       |

Table 1 continued on next page
Table 1  Continued

| Oncolytic virus | HSV gene mutations (deletion: Δ; inactivating mutation: -) | Transgenes | Reference |
|-----------------|------------------------------------------------------------|------------|-----------|
| R5141           | Deletion of residues 68-78 in gB, 1-140 in gC, and 1-33 in gD, gC V34S substitution | IL13 fused to gD and gC | 125       |
| R-LM113         | Deletion of residues 6-38 in gD | scHER2 fused to gD, ICP27pro-EGFP between UL3 and UL4 | 130       |
| R-LM249         | Deletion of residues 61-218 in gD | scHER2 fused to gD, ICP27pro-EGFP between UL3 and UL4 | 126       |
| rQnestin34.5    | γ34.5Δ, ICP6Δ | Nestin enh-Hsp68pro-γ34.5 and ICP6-GFP fusion in ICP6 | 48        |
| Armed vectors   |                                                            |            |           |
| bPΔ6-hPAP       | ICP6Δ | CMVpro-hPAP, ICP6-LacZ in ICP6 | 136       |
| R-LM113         | γ34.5Δ, ICP6Δ, ICP47Δ, ICP47pro-Us11 | ICP6-GFP fusion, IE4/5pro-Vstat120, Nestin enh-Hsp68pro-γ34.5 in ICP6 | 133       |
| R-LM249         | γ34.5Δ, ICP6Δ, ICP47Δ, ICP47pro-Us11 | ICP6-GFP fusion, IE4/5pro-Vstat120, Nestin enh-Hsp68pro-γ34.5 in ICP6 | 130       |
| rQnestin34.5    | γ34.5Δ, ICP6Δ, ICP47Δ, ICP47pro-Us11 | ICP6-GFP fusion, IE4/5pro-Vstat120, Nestin enh-Hsp68pro-γ34.5 and ICP6-GFP fusion in ICP6 | 133       |
| G47Δ-IL18/B7    | γ34.5Δ, ICP6Δ, ICP47Δ, ICP47pro-Us11 | ICP6-GFP fusion, IE4/5pro-Vstat120, Nestin enh-Hsp68pro-γ34.5 in ICP6 | 130       |
| G47Δ-miR12      | γ34.5Δ, ICP6Δ, ICP47Δ, ICP47pro-Us11 | ICP6-GFP fusion, IE4/5pro-Vstat120, Nestin enh-Hsp68pro-γ34.5 in ICP6 | 133       |
| G47Δ-mAngio     | γ34.5Δ, ICP6Δ, ICP47Δ, ICP47pro-Us11 | ICP6-GFP fusion, IE4/5pro-Vstat120, Nestin enh-Hsp68pro-γ34.5 in ICP6 | 130       |
| G47Δ-PF4        | γ34.5Δ, ICP6Δ, ICP47Δ, ICP47pro-Us11 | ICP6-GFP fusion, IE4/5pro-Vstat120, Nestin enh-Hsp68pro-γ34.5 in ICP6 | 133       |
| HSV1790         | γ34.5Δ | CMVpro-GM-CSF in γ34.5 | 150       |
| HSV-γCD         | ICP6- | CMVpro-yeast CD | 147       |
| HSV-PNP (M016)  | γ34.5Δ | Egr1pro-PNP in γ34.5 | 152       |
| M002            | γ34.5Δ | Egr1pro-miR12 in γ34.5 | 166       |
| M012            | γ34.5Δ | Egr1pro-bacterial CD in γ34.5 | 148       |
| M032*           | γ34.5Δ | Egr1pro-hI-10 in γ34.5 | 169       |
| MGH2            | γ34.5Δ, ICP6- | HSVIE4/5pro-CYP2B1, CMVpro-shiCE, ICP6-GFP fusion in ICP6 | 150       |
| NV1034           | ULS 6 (duplicated), ULS 6Δ, Joint deletion (1 copy of ICP0, ICP4, γ34.5, ICP47Δ, Us11Δ, Us10Δ) | ICP47pro-LacZ in ICP4, ICP4 enh-TKpro-GM-CSF, HSV-2 gG, PK in joint | 87 |
| NV1042           | ULS 6 (duplicated), ULS 6Δ, Joint deletion (1 copy of ICP0, ICP4, γ34.5, ICP47Δ, Us11Δ, Us10Δ) | ICP47pro-LacZ in ICP4, ICP4 enh-TKpro-GM-CSF, HSV-2 gG, PK in joint | 87 |
| oHSV-NIS        | γ34.5Δ, ICP6- | CMVpro-Nis in ICP6, ICP6-GFP fusion | 145       |
| oHSV-TRAIL      | γ34.5Δ, ICP6- | IE4/5pro-sTRAIL in ICP6, ICP6-LacZ fusion | 155       |
| OncoVex(GMCSF)* | (Talimogene laherparepvec) | CMVpro-GM-CSF in γ34.5 | 56        |
| OV-Chase        | γ34.5Δ, ICP6- | IE4/5pro-Chase, ICP6-GFP fusion in ICP6 | 179       |
| R8308           | γ34.5Δ | Egr1pro-miR10 in γ34.5 | 171       |
| RAMBO           | γ34.5Δ, ICP6- | ICP6-GFP fusion, IE4/5pro-Vstat120 in ICP6 | 176       |
| rQT3            | γ34.5Δ, ICP6- | ICP6-GFP fusion, IE4/5pro-Vstat120 in ICP6 | 176       |
| rRp450*         | ICP6Δ | ICP6pro-CYP2B1 in ICP6 | 149       |
| Synco-B18R      | γ34.5Δ, syn- | UL38pro-B18R, CMVpro-eGFP in joint | 53        |
| T-TSP-1         | γ34.5Δ, ICP6- | CMVpro-TSP1, ICP6-LacZ fusion in ICP6 | 177       |
| VAE             | γ34.5Δ, ICP6- | ICP6pro-endo-angio fusion in ICP6 | 174       |

AFP, aequorea fluorescent protein; BAC, bacterial artificial chromosome; BBD, beclin binding domain; CEA, carcinoembryonic antigen; CD, cytosine deaminase; Chase, chondroitinase ABC; CYP2B1, cytochrome P450; eGFP, enhanced green fluorescent protein; endo-angio, endostatin-angiostatin; enh, enhancer; fluc, firefly luciferase; gD, HSV glycoprotein D; Gluc, β-glucuronidase; h, human; IE4/5, immediate-early gene 4/5; IL, interleukin; LacZ, β-galactosidase; m, mouse; minpro, minimal promoter; Msi, musashi1; NIS, sodium/iodide symporter; NTR, E. coli nitroreductase; PNP, E. coli purine nucleoside phosphorylase; PK, protein kinase; pro, promoter; RR, ribonucleotide reductase; TIMP3, tissue inhibitor of metalloproteinases 3; TK, thymidine kinase; shI-CE, secreted human intestinal carboxylesterase; smAngio, secreted mouse angiostatin; sTRAIL, secreted TNF-related apoptosis-inducing ligand; Tcf, response element; TSP1, thrombospondin-1; Vstat120, vasculostatin.

oHSVs in clinical trial are marked with *.
reduced in growth-arrested cells so capped mRNAs, including HSV transcripts, are poorly translated. Thus, tumor cells lacking negative regulation of their initiation complexes will be susceptible to ICP6 mutant oHSV, while normal cells will shut down viral protein production. In addition, the ICP6 N-terminal RHIM domain binds and activates RIP3, triggering necrosis.\textsuperscript{14} ICP6 also plays a role in blocking TNFα- and Fasl-induced apoptosis, likely through interactions with caspase 8 and RIP1.\textsuperscript{19,20} This antiapoptotic effect was not seen with hrR3, suggesting the inhibitory domain may be in the C-terminus.\textsuperscript{20} These actions confer further specificity to tumor cells, which tend to be resistant to apoptosis. As additional safety features, ICP6 mutants are somewhat temperature-sensitive and hypersensitive to antiviral nucleoside analogs and DNA replication inhibitors.\textsuperscript{9,21}

Aside from the colon crypts, epidermal and bone marrow progenitors, and activated splenic immune cells, most normal tissues in humans are not actively replicating. Removing ICP6 limits the ability of the HSV-1 to replicate in postmitotic cells and directs the virus toward dividing tumor cell populations. For these reasons, deletion or inactivation of ICP6 creates a safer oHSV while targeting actively growing tumors. ICP6-deleted rPr450 is currently in a clinical trial for liver tumors (see http://clinicaltrials.gov/show/NCT01071941). ICP6 mutations have been combined with other single mutations in order to enhance safety and tumor specificity: G207 from R3616,\textsuperscript{22} 1716-6 from 1716,\textsuperscript{23} MG18L from R7041,\textsuperscript{24} and Δ68H-6 from Δ68H\textsuperscript{23} (Table 1). The C-terminus of ICP6 is responsible for its ribonucleotide reductase activity, which is why many oHSVs have inserted a LacZ fusion within this region of the gene to inactivate it.\textsuperscript{22–25} The N-terminus of ICP6 is responsible for expediting the elf4G interaction with elf4E and binding RIP3, and is present in several oHSVs. Going forward, it will be important to ascertain which functions of ICP6 are related to oncolytic activity.

UL2/UNG (E)

UL2, uracil DNA glycosylase, is another HSV-1 gene involved in nucleotide metabolism, which when removed attenuates neurovirulence, neuroinvasiveness, and reactivation.\textsuperscript{26} Uracil-DNA glycosylases prevent mutagenesis by excising uracil from DNA molecules and signaling the base excision repair pathway. OHSV 3616UB lacks γ34.5 and UL2, and is hypersensitive to ganciclovir.\textsuperscript{27} It demonstrated oncolytic efficacy in six brain tumor cell lines as well as in xenografts, and could not replicate in mature neurons in vitro or in vivo.\textsuperscript{27}

PATHOGENICITY AND ANTVIRAL SUPPRESSION

Mammalian organisms have evolved multiple mechanisms for detecting and disabling intracellular pathogens. In order for HSV-1 to replicate its genome and create the next generation of virus, it must cloak itself or actively disrupt host responses to foreign pathogens. Many of the HSV-1 genes which inhibit the host cell's ability to initiate apoptosis or hamper viral replication are nonessential for viral replication in cancer cells, and therefore provide mutation targets for creating oHSV.

γ34.5/RL1 (L)

γ34.5, one of the most frequently mutated genes for creating oHSVs, has many functions. HSV-1 is diploid for the γ34.5 gene, and mature virions contain the protein in their tegument in order to deliver it upon entry.\textsuperscript{2} γ34.5 promotes the rapid dephosphorylation of the translational initiation factor elf2α by activating protein phosphatase 1 (PP1α).\textsuperscript{28} When elf2α is phosphorylated, elf2β is unable to exchange GDP for GTP and methionine-tRNA is not loaded into the ribosome, preventing translation from initiating.\textsuperscript{29} Dephosphorylation of elf2α prevents host translational shutoff induced by virus infection, thereby allowing the continued production of viral proteins.\textsuperscript{28} EIF2α is phosphorylated by several kinases (PKR, PERK, GCN2, HRI) activated by environmental stresses or upon detection of foreign pathogen associated molecular patterns (PAMPs) such as viral DNA and double-stranded RNA, and dephosphorylated by PP1α bound to GADD34.\textsuperscript{29} The C-terminus of γ34.5 is homologous to GADD34 and can replace GADD34 for PP1α activation.\textsuperscript{30} Thus, treatment with chemotherapeutics that induce GADD34 expression can enhance γ34.5-deficient oHSV replication and cytotoxicity.\textsuperscript{31–33} Tumor cells often lack the metabolic control of translation or antiviral/stress responses observed in nontransformed cells, allowing oHSV lacking γ34.5 to replicate. Many tumors also overexpress elf2α, coinciding with the down regulation of the elf2 kinase, effectively disabling the tumor’s ability to halt viral protein translation, even in the absence of γ34.5.\textsuperscript{29}

In addition to disrupting the translational shutoff pathway, γ34.5 interrupts autophagic vesicle maturation,\textsuperscript{34} blocks the tank binding kinase (TBK-1)-mediated interferon-stimulated gene (ISG) signaling pathway,\textsuperscript{35} interacts with proliferating cell nuclear antigen (PCNA),\textsuperscript{36} and relocates p32 (HABP1/gC1qR) for nuclear egress.\textsuperscript{37} Autophagic vesicles, or autophagosomes, are created by a collection of autophagy factors and kinases supported by the mitochondrial protein Beclin-1 (BCN1; yeast homologue Atg6).\textsuperscript{38} BCN1 binds to PI3 kinase class III (PI3KcIII) and other ATG co-factors, to convert LC3-I into LC3-II and recruit ATG components into forming autophagic vesicles.\textsuperscript{38} γ34.5 disrupts autophagosome formation by binding to BCN1 via its BCN1 binding domain (BBD; amino acids 68-87), preventing BCN1 binding to ATG/PI3KcIII cofactors.\textsuperscript{39,40} Autophagy has both positive and negative impacts on tumorigenesis and maintenance,\textsuperscript{26} but γ34.5 BBDα oHSV (Δ68H-6) replicates in and kills glioma cells similarly to γ34.5+ oHSV.\textsuperscript{41} Deletion of the γ34.5 BBD somewhat attenuated neuropathogenicity.\textsuperscript{39,40} Therefore, ICP6 inactivation was combined with BBD deletion in Δ68H-6 to eliminate pathogenicity.\textsuperscript{21} TBK-1 normally functions as a messenger protein to activate IRF3, which then activates interferon α/β and ISGs. γ34.5 binds TBK-1, preventing it from activating the IRF3 complex.\textsuperscript{35} Thus, HSV lacking γ34.5 are highly susceptible to interferon (IFN) inhibition. The function of γ34.5 binding to PCNA and its shuttling between the nucleus and cytoplasm is unknown.\textsuperscript{36,41} P32 relocalizes to the nuclear envelope upon binding γ34.5 to facilitate nuclear egress, and knockdown of p32 decreased the replication of the virus.\textsuperscript{17}

The γ34.5 gene is the major determinant of HSV neuropathogenicity, although the exact mechanism(s) by which γ34.5 contributes to herpes simplex encephalitis is unclear.\textsuperscript{42} MHC class II cell surface complexes are increased after infection of glioma cells with γ34.5-deleted R3616, as compared to wild-type or mock infected.\textsuperscript{43} γ34.5-deleted HSV-1 gains neuropathogenicity in IFNα/βR- or PKR-deficient mice.\textsuperscript{44} Thus, many oHSVs being clinically evaluated have both copies of γ34.5-deleted: G207, G47Δ, 1716, OncovEX\textsuperscript{45} (M032 and M032 (Table 1). Unfortunately, γ34.5-deleted oHSVs (1716, G207, R3616), but not G47Δ or Δ68H-6, replicate poorly, if at all, in glioblastoma stem cells.\textsuperscript{46,47} oHSVs containing only 1 copy of γ34.5 have been constructed (i.e., NV1020), but the contribution of the γ34.5 deletion is unclear because of other mutations present in these oHSVs. To improve safety and reduce the chance of second-site suppressors, deletion of γ34.5 was combined with ICP6 inactivation to create G207, the first oHSV to enter clinical trial in the US.\textsuperscript{22,46,47} Because deleting γ34.5 attenuates virus replication.
even in cancer cells, a strategy to confine γ34.5 expression to cancer cells was developed. OH5V rQnestin34.5, with the endogenous γ34.5 genes deleted, has a γ34.5 gene cassette controlled by a nestin promoter so it is only expressed in cancer cells expressing nestin64 (see Transcriptional Targeting). An unbiased strategy has been to select more effective oHSV by passaging virus in tumors or tumor cells. The ICP47 deletion (see below) was isolated by passaging γ34.5-deficient HSV-1 in non-permissive SK-N-SH tumor cells.49 This second-site suppressor of γ34.5 was due to immediate-early expression of Us11 because of deletion of its late promoter.50 A similar strategy was followed by passaging M002 in D54MG glioma cells in culture or glioma xenografts. The in vivo passaged virus was more efficacious in both immune-deficient D54MG and syngeneic Neuro2a brain tumor models, while the in vitro passaged virus had increased neurovirulence.51 However, no analysis was performed to identify the genetic alterations.

An alternate strategy to complement the loss of γ34.5 is to express genes from other viruses that evade PKR-mediated protein shutoff or IFN-mediated antiviral responses. CMV IFS1, which prevents PKR activation, has been inserted into γ34.5Δ R3616 to generate C134.52 C134 infection of glioma cells, compared to its γ34.5Δ parent, overcame the block in protein synthesis, replicated better in tumors, and was more efficacious in extending survival of glioma-bearing mice, but maintained safety after intracranial injection.52 Vaccinia virus B18R, a secreted IFNβ/β decoy receptor, is expressed in Synco-B18R under control of the Late UL38 promoter, so it is only expressed in tumor cells after oHSV replication.53 Synco-B18R was able to replicate in tumor cell lines poorly permissive to oHSV and was somewhat more efficacious in vivo, but was safe after intravenous administration.53

ICP47/Us12 (IE) + Us11 (L→IE)
ICP47 blocks the TAP protein channel preventing peptide loading onto MHC I protein and subsequent MHC I expression.7 The shroud virus-infected cells from HSV-1-specific CD8+ T-cells, but can trigger an NK cell response due to the lack of MHC I on the infected cell’s surface.65 The TAP channel blocking activity of ICP47 is species-specific, making studies of ICP47 activity in mice not representative of the protein’s activity in humans. ICP47 is deleted in G47Δ and several other oHSVs (OncoveXΔ34.5, SUP-1 (Table 1)) to enhance immune responses against virus-infected tumor cells and antitumor immunity.55-57 Deletion of the ICP47 ORF and Us11 promoter places Us11 under control of the ICP47 IE promoter. Us11 is a true gene that binds dsRNA-dependent elf2α kinase (PKR), precluding it from binding dsRNA and phosphorylating elf2α.58,59 IE expression of Us11 complements the deletion of γ34.5 in nonpermissive cells by keeping elf2α dephosphorylated and protein translation unhindered. G47Δ and SUP-1 replicate in cells nonpermissive to γ34.5-deficient HSV and better in permissive cells, yet retain a lack of pathogenicity.55-60

RIGI/MDA5 are sensors that detect RNA in the cytoplasm and activate IRF3, leading to induction of the ISG pathway. Us11 directly binds RIGI and MDA5 preventing activation of IRF3 and production of IFNβ.61 This interaction is RNA independent and mediated by the C-terminus of Us11, which is also where the PKR and dsRNA binding pockets of the protein are located.61,62 Us11 excels at deactivating RNA-mediated immune responses, so that expression of Us11 rescues Sindbis virus replication, which is very sensitive to the RNA sensor activated ISGz.61 Us11 also directly binds IIS 2’s’ oligodeoxynucleotide synthase (2’S’OAS) to prevent it from recognizing dsRNA and subsequently activating RNaseL.63 Interruption of 2’S’OAS signaling allows the virus to express its mRNAs without being shut off by host defenses. Us11 also prevents cell death from staurosporine, associates with nucleolin within the nucleus, interacts with nuclear transport machinery during viral replication, and moderately inhibits its autophagy.52-54,65 How or whether these other functions of Us11 enhance the replication of γ34.5-deficient oHSV is unclear, however, IE expression of Us11 rescues the growth of γ34.5-deficient virus in nonpermissive tumor cells, while still being safe in mice.55,60

Us3 (L)
Us3 is a serine-threonine protein kinase with substrate specificity overlapping PKA and Akt,66,67 affecting a multitude of antiviral host responses. One of the earliest functions identified was prevention of apoptosis in infected cells, possibly by phosphorylating PKA substrates, blocking proapoptotic BAD protein activation, and/or eliciting a prosurvival signaling pathway.68 Defects in apoptotic pathways are common in tumor cells, while inhibition of apoptosis is important for virus replication in normal cells. Thus, Us3-deleted R7041 induced much greater apoptosis in normal HUVEC than its wild-type revertant, while inducing similar low levels in cancer cells.69 Us3 phosphorylates a large number of viral and cellular proteins, affecting many pathways in infected cells: dUTPase (UL50) to increase enzymatic activity;70 gB to enhance virus replication in vivo;71 p65 to inhibit NF-κB activity and innate immune responses;72 IRF3 to inhibit IFNb expression;73 IFNγ to abrogate expression of IFNγ-dependent genes;74 and TSC2 to activate mTORC1 and stimulate translation.67 It also indirectly downregulates cell surface expression of MHC 1, increasing HSV-specific CD8+ T-cells in mice.75 These activities promote Us3-deleted oHSVs tumor specificity due to deficiencies in innate immune responses, as well as contribute to reducing neuroinvasiveness, neuropathogenicity, and peripheral pathogenicity of Us3-deleted oHSV.76

Us3-deleted HSV-1 (R7041) and HSV-2 (L1BR1) were shown to have oncolytic activity, with greatly reduced replication compared to wild-type HSV in normal cells in vitro, and elevated replication in tumors in vivo compared to normal tissue.69,77 Chemotherapy increased apoptosis in L1BR1, but not wild-type, infected cancer cells.77 R7041 was safe after intravenous injection in immune-deficient mice and intraperitoneal injection in immune-competent mice.69 However, it was insufficiently safe in the brain, in contrast to γ34.5Δ virus, so MG18L containing an additional inactivating LacZ insert in ICP6 was constructed.78 MG18L induces increased levels of apoptosis in glioblastoma stem cells (GSCs) in vivo and in vitro.79 Because Akt activation is elevated after infection with Us3-deleted HSV, the combination with PI3K/Akt inhibitors was evaluated and found to synergize in cancer cell lines and GSCs, through increased apoptosis.78-80

ICP0 (IE)
ICP0 encodes a RING finger ubiquitin E3 ligase that targets cellular proteins.81 ICP0 targets PML or ND10 bodies and other host factors designed to silence HSV-1 genomes and induce IFN signaling for ubiquitination and degradation.82 Thus, ICP0-null HSV-1 is extremely sensitive to IFN and PML-mediated disruption of the viral lifecycle.82 In multiple tumors, PML is downregulated, making them permissive for ICP0-null oHSV.83 ICP0 is also involved in 4E-BP1 degradation and promoting elf4E phosphorylation, facilitating elf4F complex formation in quiescent cells, important for HSV replication.84 oHSV KM100 has mutations which disable the ICP0 gene, as well as VP16.85 It is able to grow in IFN-deficient breast cancer cell lines and demonstrated therapeutic efficacy using the
immunocompetent mouse FVB breast cancer model. IC0 truncation mutant HSV-1 (n212) replicated better in mouse cancer cells in vitro than KM100, while the efficacy of the two was the same in an immunocompetent mouse tumor model. Mice receiving KM100 that survived the initial tumor were protected from tumor rechallenge, demonstrating that the virus elicits a memory immune response to the tumor. Another IC0-null oHSV, JD0G replicates in osteosarcoma U2OS and glioblastoma U251 cells. The ability of IC0 mutants to replicate in a variety of human and mouse tumor cell lines suggests that transformed cells complement IC0 defects, while untransformed cells remain nonpermissive, making IC0 a good target for designing oHSVs with specificity for tumor cells.

UL56 (L)
UL56 is another gene associated with pathogenicity and neuroinvasiveness, as removing it attenuates the virus. oHSV HF10 has a number of deletions and insertions in the genome, resulting in the lack of expression of UL43, UL49.5, UL55, and UL56. HF10 has demonstrated efficacy in a variety of preclinical models and entered early phase clinical trials for breast and head and neck cancer. NV1020, which was initially developed as a vaccine (R7020), and NV1023 are also deleted for UL56, along with ICP47 and a single copy of ICP0, ICP4, and γ34.5. Whether UL56 contributes to tumor selectivity is unknown, but it is a good candidate for mutation when creating a safer oHSV.

OTHER HSV-1 FUNCTIONS
The proteome of HSV-1 is rather well defined due to extensive study; however, the functions of many proteins still remain unknown. Because of the large genome size and number of nonessential viral genes, the opportunities for identifying additional genes endowing oncolytic activity remains. Some mutations have been incorporated into oHSV, without their contribution being defined. The following are other mutated genes present in oHSVs, whose roles are not well defined in relationship to oncolytic activity.

VP16/UL48 (L)
VP16 is delivered during entry of HSV-1 via the tegument. It plays a role in aiding the transcription of IE genes during initial infection and during reactivation from latency. In KM100, VP16 is mutated along with ICP0. Interestingly, combining a VP16 mutant lacking the C-terminus with ICP0-null (KM110), produces a less cytopathic, more debilitated virus than with VP16 mutation in1814 (in KM100), which removes the trans-activating activity of VP16. This difference was also exhibited in cancer cell lines.

UL24 (L)
The UL24 gene overlaps TK, so some TK deletions also contain UL24 mutations (i.e., RH105), although not dlspTk, and G92A. UL24 causes the dispersal of nucleolin throughout the nucleus. UL24 single mutants are defective in establishing latency and reactivation, replicating in the eye, and causing ocular disease. UL24 mutants can also have a syn phenotype, whereby infected cells form syncyta. NV1020 contains a UL24 deletion as a result of removing TK, as well as deletion of UL56. NV1020 is efficacious in a variety of colon, gastric, and prostate cancer models and safe in patients, although the role of the UL24 deletion in its oncolytic activity is unknown.

OTHER ONCOLYTIC HERPESVIRUSES
HSV-2
HSV-2, another human alphaherpesvirus primarily associated with genital disease, has a genome that is very similar to HSV-1, both in genomic organization and protein coding sequences. In a comparison between ICP0Δ HSV-1 and HSV-2, HSV-2 dICP0 was more cytopathic in mouse breast cancer cells than HSV-1 dICP0, but had much lower virus burst sizes. In vivo, in an immunocompetent mouse breast tumor model, only HSV-1 dICP0 significantly extended survival.

The HSV-2 UL39 gene encodes ICP10, a homolog of HSV-1 ICP6 that contains a unique N-terminal domain proposed to encode a serine/threonine protein kinase (PK). Thus, in addition to ribonucleotide reductase activity, ICP10 is a constitutively active growth factor receptor that directly interacts with RAS-GAP to activate RAS-GTP and stimulate the RAF/MEK/ERK signaling pathway, which prevents apoptosis in infected cells. HSV-2 ICP10 PK deletions have been tested for oncolytic efficacy due to the inability of HSV-2 to replicate in noncycling cells without ICP10/PK, and the presence of constitutive RAS signaling and defective apoptosis in many tumors. FusOn-H2 and DeltaPK (HSV2ΔPK) are oHSV2 which have deletions of the PK domain of ICP10. Both do not replicate in noncycling normal cells, induce apoptosis, and engender stallart therapeutic efficacy in melanoma, esophageal, and breast cancer orthotopic tumor models. FusOn-H2 exhibited no toxicity after i.v. injection in BALB/c mice at a dose 3-logs higher than the wild-type lethal dose, but one out of five mice died after intracerebral injection at 107 pfu. HSV2ΔPK was safe after foodpad injection and in a clinical vaccine trial where three injections of 2 x 107 pfu were administered subcutaneously.

HSV-2 Us3 has many of the same functions as HSV-1 Us3, including preventing apoptosis, but lacks some of the HSV protein kinase substrates. Thus, HSV-2 Us3 deletions are only minimally attenuated for neurovirulence compared to HSV-1 Us3 deletions. HSV-2 L1BR1 was safe when injected into mouse footpads, but not for intracranial or corneal injections, and induces apoptosis in neurons. In SW1990 pancreatic tumor implanted mice, L1BR1 was significantly better than oHSVs R3616 and hrR3 in inhibiting tumor growth.

Bovine herpesvirus-1
BHV-1, an alphaherpesvirus that affects cattle, causes fever and respiratory disease. BHV-1 has a very restricted host range, likely regulated by IFN. This suggested that it might be inherently oncolytic, like myxoma virus, killing human tumor cells and not normal human cells. The majority of the NCI panel of established human tumor cell lines are permissive to BHV-1 infection and cytotoxicity, with mutations in KRAS associated with virus replication. Direct exposure to BHV-1 seems to be sufficient to induce cell death in many cancer cells, even when replication does not occur.

Equine herpesvirus type 1
EHV-1 is an alphaherpesvirus mainly associated with equine disease that does not infect humans, but does infect human cells in culture. It uses the equine MHC-I protein as its entry receptor, which has regions highly conserved across species, including humans. An attenuated EHV-1, deleted for glycoproteins gl and gE (L11ΔgldΔgE), was found to replicate in and kill a number of human glioma cell lines. Given that many tumors, and especially glioblastoma, often
TRANSCRIPTIONAL AND MICRO-RNA TARGETING

Understanding the lifecycle of HSV-1 allows researchers to target tumor cell populations by altering expression of viral genes to control productive infection in select cell types. ICP4, one of five IE genes, is an essential gene and the major virus trans-activator responsible for activating transcription of the E and L genes. Because ICP4 is essential, regulating its expression with cell-specific transcriptional regulatory sequences can restrict virus replication and oncolytic activity to cells expressing those transcription factors. Thus, oHSV can be targeted to cancer cells based on transcription factor expression in those cells. Alternatively, ICP4 expression can be silenced in normal cells by cell-specific miRNAs targeting ICP4 mRNA containing miRNA target sequences.

Several oHSVs have been constructed with their endogenous ICP4 genes deleted and an ICP4 coding sequence controlled by a cell- or tissue-specific promoter inserted, which confers specificity to a tumor tissue. These are transcriptionally-targeted oHSVs because they are only able to replicate in cells where expression of a tumor-specific transcription factor drives ICP4 transcription. G92A is the prototypic vector, targeting liver cancer via insertion of ICP4 under control of the albumin promoter transcription. G92A replicates in albumin-expressing Hep3B hepatoma cells, but not the albumin-negative HT29 colon carcinoma cells. In nude mice, G92A completely inhibited the growth of Hep3B, but not prostate PC3, tumors. D12.CALP was similarly constructed, but contains the calponin promoter driving ICP4. Calponin is expressed in many postmitotic cells, but overexpressed in several sarcomas. Thus, d12.CALP was efficacious against human leiomyosarcoma, but not calponin-negative osteosarcoma xenografts.

The Wnt/β-catenin pathway is upregulated in the majority of colorectal cancers and many cancer stem cells, and leads to transcriptional activation of Wnt response elements containing Tcf binding sites. In bM24-TE, a synthetic enhancer containing multiple Tcf binding sites, a 4F2 enhancer, and a CMV minimal promoter was used to drive ICP4 expression after insertion into the ICP6 locus. BM24-TE selectively replicated in and killed cancer cells with strong β-catenin/Tcf signaling (APC or β-catenin mutants), but not cancer cells with low signaling, with similar inhibition of tumor growth.

There have also been several unsuccessful attempts to use cellular promoters to target oHSVs to tumors. Human carcinoembryonic antigen (CEA) is overexpressed in several epithelial tumors. CEAICP4 was created using the CEA promoter to drive ICP4. Unfortunately, it replicated poorly in CEA-expressing cells and not at all in some high-expressing tumors cells, demonstrating that not all tumor associated promoters are good candidates for creating transcriptionally-targeted oHSV. Another problem with transcriptionally targeted oHSV is that the promoter may not behave as expected in HSV. For example, HIF-V6R-HSV, with a HIF-1α-responsive promoter driving ICP4, was active under both normoxic and hypoxic conditions. Confounding the strategy, it was found that HSV-1 infection increased transcription from the HIF responsive promoter in normoxia. In these studies, HIF-V6R-HSV was also found to have reverted back to the wt ICP4 configuration, likely through recombination in complementing cells during its isolation.

Rather than targeting expression of ICP4, a number of oHSV employ regulated expression of γ34.5 to enhance virus replication in tumor cells. This strategy was initially described with Myb34.5, which lacks ICP6 and expresses γ34.5 under a cellular E2F-responsive B-myb promoter inserted into ICP6 in γ34.5Δ MGH1 (similar construct to G207). This transcriptional targeting increased the growth of Myb34.5 in human colon cancer cells, but not hepatocytes, and extended survival of mice with liver metastases compared to parental MGH1. The nestin enhancer/Hsp78 minimal promoter drives γ34.5 expression in rQnestin34.5 and 34.5ENVE, in order to selectively target tumor cells overexpressing nestin, such as glioblastoma, some peripheral tumors, and cancer stem-like cells. Unfortunately, nestin is also expressed in neural stem/progenitor cells and other tissue stem cells, creating potential safety concerns for nestin-targeted oHSV. RQnestin34.5 and 34.5ENVE replicate well in glioblastoma cell lines and confer a survival benefit in immune-deficient mice implanted intracerebrally with glioblastoma cell lines. 34.5ENVE was also effective against patient ascites-derived ovarian cancer cells, which have increased nestin expression. Musashi1 is another gene selectively expressed in glioblastoma. Its promoter was used to drive γ34.5 expression after recombination in G207 to create KeM34.5. KeM34.5 replicated much better in glioma cells, but not musashi1-negative lung or colon cancer cells, than G207, and not in astrocytes. Midkine, upregulated in a number of tumors was used in place of the nestin enhancer to drive γ34.5 expression in oHSV-MDK-34.5 in MPNST.

Several researchers have tested a different method for targeting expression of oHSV genes, in this case silencing expression with microRNAs. MicroRNAs (miR) are small 22-28nt RNAs that signal the destruction of complementary miRNAs via the RISC complex. There are many miRNAs expressed in normal but not tumor cells, so miRNA target sequences inserted into essential HSV-1 genes can selectively inhibit virus replication and/or gene expression in normal cells, leading to selective replication in tumor cells. For example, miR-143 and -145 are expressed in most human tissues but not in prostate cancer cells. MiR-143 and -145 target sequences inserted into the 3'UTR of ICP4 (142T and 145T) blocked its expression in normal but not prostate cancer cells. The replication of CMV-ICP4-143T, an ampiclon plasmid with ICP4Δ helper HSV, in normal tissues was much more restricted than CMV-ICP4-145T. KG4:T124, containing tandem copies of a mir-124 target sequence within the 3'UTR of ICP4, was safe after intracranial injection compared to parent oHSV KG, deleted for the internal repeat region. ICP4-T124 was recombined into KGE, with an EGFR-targeted gD fusion (see Receptor Targeting), and found to be similarly effective in treating mice harboring intracranial glioblastoma stem cell GBM30 tumors as KGE. LCSOV, miR targets to miR-122a, miR-124a, and miR-let-7a, were used to repress liver-specific apoE-AAT promoter driven gH expression in liver tissue, but not hepatocellular carcinoma. LCSOV was able to replicate in miR122-negative Hep3B cells and inhibit tumor growth.

RECEPTOR TARGETING

The HSV glycoproteins stud the envelope and are responsible for binding to viral attachment factors; heparan sulfate, HVEM (HveA), and nectin-1 (HveC). Upon binding their attachment factors, the glycoproteins aid fusion of the HSV envelope with the plasma membrane. It is possible to modify one or more of the glycoproteins to create a virus that infects cells expressing a targeted receptor and/or detargets cells expressing the normal HSV-1 attachment factors. Glycoprotein C has been used as a site to insert tumor-specific receptor binding ligands or single-chain antibodies (scFv) to target reovirus, but this only removes the heparan sulfate binding..
Glycoprotein D (gD) binds to the major HSV cell surface receptors, and thus deleting gD binding domains (N-terminus (aa7–32) for HVEM and Ig-core (aa61–218) for nectin 1) and introducing ligands for tumor-specific receptors is an attractive strategy to target HSV. Two basic strategies have been used: insert a tumor-specific receptor ligand or scFv with a bispecific adapter protein containing the gD-binding domain of nectin 1 or HVEM fused to a tumor-specific receptor scFv with a HVEM or nectin 1 detargeted gD mutant, respectively. HER2 is overexpressed in a number of tumors, including breast and ovarian cancer, and glioblastoma. A HER2 targeted oHSV (R-LM249) was constructed by inserting scFv human HER2 (trastuzumab) into a gD Ig-folded core deletion. R-LM249 inhibited the growth of HER2+ ovarian and breast subcutaneous or metastatic tumors, but not HER2 SJ-RH4 rhabdomyosarcoma tumors after intratumoral or intraperitoneal injection. A similar HER2-targeted oHSV, R-LM113, replicated in and was efficacious against a PDGF-induced mouse glioma overexpressing HER2 in both immunodeficient and immunocompetent mice, and was safe after intracerebral injection. An important caveat to this approach is that HER2 scFv is human specific and does not bind mouse HER2. The use of scFv allows one to potentially target any cell surface molecule, as illustrated by other receptor-targeted oHSVs binding to human EGFR (KNE) or CEA (KNC), or IL13Rα2 (RS141), upregulated in glioblastoma. A confounding feature of this strategy is that all cancer cells must express high levels of the targeted receptor, while cancers are typically heterogeneous for receptor expression.

**GENETIC ENGINEERING OF oHSVS**

Many researchers now use bacterial artificial chromosome (BAC) systems to quickly swap in transgenes or create specific mutations more easily than classical homologous recombination in tissue culture. HSV BACs are large circular plasmids (>150 kb), which replicate in bacteria as an artificial genome. BACs are useful for cloning DNAs much larger than is possible using conventional plasmids. For example, the pM24-BAC contains the entire HSV genome with a bacterial origin of replication flanked by Cre/loxP and FLP/Frt sites inserted into the ICP6 gene. To create a new virus, a shuttle vector containing the transgene flanked by Cre/loxP sites and a stuffer sequence flanked by a Frt/Flp site is recombined into the HSV-BAC with Cre recombinase. The recombined HSV-BAC plasmid is harvested from bacteria and cotransfected into mammalian cells with a Flp recombinase plasmid to remove the BAC and stuffer sequence, and infectious recombinant virus harvested. This method results in a high frequency of recombinant virus. HSV-BACs can also be used to introduce specific mutations in genes, for example through the use of lambda phage Red recombinase.

Aside from BACs, the very recent development of the CRISPR/Cas9 mutagenesis system allows researchers to quickly insert or remove genes/sequences into the HSV genome without cloning into BAC plasmids, decreasing the time it takes to create a new HSV. The CRISPR/Cas9 system is a defense platform for bacteria to target the DNA genomes of bacteriophages. Cas9 is a bacterial nuclease complex, which recognizes a single-stranded guide RNA complementary to a region of dsDNA. The Cas9 enzyme uses the guide RNA to cleave complementary DNA. However, the accuracy of this cleavage is not perfect and mismatches of the guide RNA sequence with the targeted DNA can result in aberrant DNA cleavage. Recently, the CRISPR/Cas9 system was used to insert green fluorescent protein (GFP) into HSV-1, and to introduce gene-specific mutations or repair mutations. The CRISPR/Cas9 system is rapidly evolving beyond mutagenesis to gene regulation, with nucleic-acid deficient Cas9 fused to functional effectors such as transcriptional activators/repressors. CRISPR/Cas9 could also be used to direct proteins to DNA sequences within cancer cells to disrupt oncogenic super-enhancers, epigenetic modifications, or transcriptional complexes.

**oHSV-1 EXPRESSING REPORTER OR THERAPEUTIC GENES**

Transgenes come in several flavors for creating vectors. Genes are added to visualize the virus’ spread, make the virus more cytotoxic to a specific tumor cell population, elicit a targeted immune response, and/or modify the tumor microenvironment. To this end, researchers have outfitted multiple oHSV vectors with imaginative genes to create better vectors. Vectors which express cytotoxic or immune-stimulatory transgenes are usually termed “armed” oHSV, and in the following, we will discuss some of the genes and control mechanisms inserted into several armed vectors.

**Reporter genes**

The *Escherichia coli* LacZ gene encodes β-galactosidase (β-gal), which cleaves β-bonded sugars, like lactose, into single moieties. A chromogenic substrate of β-gal, termed X-gal, turns blue upon cleavage of its β-bonded sugar, allowing researchers to visualize cells expressing β-gal. LacZ can be inserted into oHSVs in order to monitor their infection of cells *in vitro* and *in vivo*. Several oHSVs have LacZ inserted into the ICP6 gene, derived from hrR3, in order to disrupt ICP6 gene activity and allow for easy monitoring of viral spread (*i.e.*, G207, G47Δ, MG181 (Table 1)). GFP expression, for example in NV1066, can also be imaged *in vivo* using fluoroscopic endoscopy. The sodium iodide symporter (NIS) can be monitored noninvasively by CT/SPECT after infected cell uptake of 131I or 125I. In addition, oHSV-NIS can be combined with cytotoxic radiotherapy to enhance antitumor efficacy. The ability to monitor virus biodistribution and replication in live animals and potentially patients provides an important avenue to follow oHSV therapy.

**Cytotoxic transgenes**

Theoretically, the most straightforward way to increase the efficacy of an oHSV is to arm it with a transgene that is toxic to nearby noninfected tumor cells, in addition to the virus’ own cytotoxicity. Expression of prodrug-activating enzymes, suicide gene therapy, is the most common strategy. HSV-TK is the prototypic “suicide gene”, converting GCV to GCV-monophosphate, however the toxic metabolite also blocks HSV replication, thereby ablating further virus spread. Cytosine deaminase (CD), not found in humans, converts 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU), a highly toxic pyrimidine antimetabolite chemotherapeutic. HSV-1yCD and M012 express yeast and bacterial CD, respectively, and the combination with 5-FC significantly increased tumor cell killing, including of noninfected cells (bystander effect), and tumor growth, but not with CD parental viruses. Other “suicide genes” successfully utilized in oHSV include: rat cytochrome P450 (CYP2B1) in rRP450 and MGH2, converting cyclophosphamide (CPA) into toxic phosphoramide mustard; secreted intestinal carboxylesterase (CE) in MGH2, for the conversion of irinotecan (CPT-11) to SN-38;
bacterial nitroreductase (NTR) in HSV1790, for the conversion of BC1954 to DNA crosslinker 4-hydroxylamine; and E. coli purine nucleoside phosphorylase (PNP) in HSV-PNP, for the conversion of 6-methylpurine-2’-deoxyriboside to 6-methylpurine. It is important to bear in mind that some of the toxic metabolites, such as 5-FU and SN-38, can also inhibit HSV replication. MGH2 contains two suicide genes, CYP2B1 and CE, and the combination of MGH2 + CPA + CPT-11 was much more effective than MGH2 with either prodrug alone, in an intracranial glioma model. Another cytotoxic strategy is to express secreted TRAIL, which induces apoptosis after binding to death receptor complexes that are often upregulated in tumor cells. oHSV-TRAIL extended the survival of mice bearing TRAIL- and oHSV-resistant intracerebral gliomas, and was associated with greatly increased apoptosis.

Immune stimulatory transgenes

Although a lively debate is still ongoing, more and more data suggests that a driving force behind oncolytic virotherapy’s success is due to immune responses elicited against the tumor. Whether stimulation of the immune system benefits or hinders oHSV therapy is debated due to the efficacy observed in immunodeficient models, which have no adaptive immune system, and the deleterious effects of the innate immune system. However, it is clear that robust antitumor adaptive immune responses are elicited by oHSV, as well as protective immune memory, suggesting that activation of the immune system is ultimately responsible for destroying the tumor and preventing its reoccurrence. Currently, there are several oHSVs that take advantage of stimulating the immune system by expressing immune-stimulatory factors to create a robust T-cell-mediated clearance of the tumor.

Granulocyte macrophage colony stimulating factor has been cloned into several oHSVs (NV1034 and OncoVEXGMCSF). Granulocyte macrophage colony stimulating factor stimulates myeloid lineage precursor cells to differentiate, as well as recruiting and activating macrophages and dendritic cells. In immunocompetent mouse models, the expression of granulocyte macrophage colony stimulating factor had only small or no enhanced efficacy over nonarmed oHSV. OncoVEXGMCSF or currently named Talmogene laherparepvec (T-Vec), the first “armed” oHSV to enter clinical trial, has demonstrated promising efficacy in patients with metastatic melanoma after intratumoral injection, with induction of local and systemic melanoma-specific T cells. In the pivotal phase III OPTIM trial, T-Vec-treated patients had a significant improvement in the durable response rate (16 versus 2% for controls) and a trend toward improved overall median survival.

Using the Flip-Flop HSV-BAC system, a number of immune modulatory transgenes have been inserted into G47Δ (IL-12, IL18, soluble B7.1, and Flt3L), including multiple transgenes in G47Δ-IL18/B7, a heterodimeric cytokine, acts directly to enhance Th1 and cytotoxic T-cell responses, and stimulates IFNγ with its associated immune effects. IL-12 has been one of the most effective antitumor cytokines expressed from oHSV; M002 in brain tumors, NV1042 in squamous cell carcinoma and metastatic prostate cancer, and G47Δ-mIL12 in glioblastoma and malignant peripheral nerve sheath tumors. With this success, an oHSV expressing human IL-12 has been constructed, M032, that was safe after intracranial injection in nonhuman primates and is currently in a phase 1 clinical trial for recurrent glioblastoma (http://clinicaltrials.gov/show/NCT02062827). IL-12 also has antiangiogenic activity, which enhances oHSV efficacy in human glioblastoma models in immunodeficient mice. In contrast, treatment of intracerebral gliomas with oHSV expressing immunosuppressive IL-10 (R8308) was no better than mock treatment. In order to prime the adaptive immune response, xenogeneic tumor antigens can be expressed in the tumor, such as prostatic acid phosphatase (PAP) in bPΔ6-hPAP for prostate cancer.

Tumor microenvironment modifying transgenes

Many tumors create a special environment allowing them to grow faster and invade nearby tissues. Growing tumors require new blood vessel formation, angiogenesis, to supply their growing peripheries with nutrients and oxygen. These new vessels also allow infiltration of tumor-associated macrophages, which benefit tumor growth. Neovascularization is promoted by secretion of vascular endothelial growth factor (VEGF) and other angiogenic factors. G47Δ-mAngio encodes the antiangiogenic peptide angiostatin inserted into the IPC6 locus. With G47Δ-mAngio reduced angiogenesis in glioblastoma stem cell and orthotic tumor models, as well as conferring a survival advantage over the empty control virus. The VAE virus is very similar, but expresses a fusion endostatin-angiostatin peptide to dampen angiogenesis. These viruses work under the principle that inhibiting angiogenesis will prevent tumor growth by blocking new blood vessel formation. Other oHSVs expressing antiangiogenic factors include platelet-factor-4, G47Δ-PF4, to inhibit endothelial cell growth and migration; Vstat120, extracellular fragment of brain-specific angiogenesis inhibitor 1, expressed by RAMBO and 34.5ENVE; thrombospondin-1, a naturally occurring antiangiogenic factor and matrix metalloproteinase (MMP)-9 inhibitor, by T-TSP-1; and endostatin, by HSV-endo.

The tumor extracellular matrix poses a problem for oHSV therapy. Many tumors create an extensive extracellular matrix that limits cell-to-cell interactions within a tumor, and thus cell-to-cell spread of oHSV. MMPs chew through this environment, which opens space for virus transfer. However, MMPs are known to increase the proliferation of many tumors and often lead to metastasis. To avoid this, OV-Chase expresses the bacterial chondroitinase-ABC, which increases interstitial diffusion while maintaining the structural composition of the extracellular matrix. OV-Chase was shown to spread better in glioblastoma spheroids in vitro, and increased the survival over nonchondroitinase-ABC expressing rHSVQ. In a reverse approach, rQT3 virus expresses an inhibitor of matrix metalloproteinases, tissue inhibitor of metalloproteinases 3 (TIMP3). rQT3 inhibited the growth of MPNST tumors in mice and MMP activity, and reduced vascular density.

CONCLUSION

There has been an explosion of research on oHSV in the last 25 years, since genetically-engineered HSV was first tested as an oncolytic virus. During that time, eight different oHSVs and “armed” oHSVs have entered clinical trial (G207, 1716, NV1020, OncoVEXGMCSF, HF-10, G47Δ, rP450, M032 (Table 1)), and OncoVEXGMCSF or T-Vec has successfully completed a pivotal phase 3 clinical trial for recurrent melanoma. Host/tumor interactions that limit virus replication and activity, be they intrinsic cellular responses, innate, or adaptive immunity, will need to be better understood in order to develop strategies to improve efficacy. The potential for developing new oHSV vectors is great, as well as strategies for combining oHSV with other therapeutic approaches to maximize outcomes. The next big step in the field will likely come from more in depth use of clinical tumor isolates to discover patterns and biomarkers associated with certain cancers. Identifying biomarkers, which distinguish cancer subtypes from one another, will allow for the development
of more targeted oHSV, either by transcriptional or receptor targeting. Advances in basic tumor biology to determine what makes a tumor cell or tumor tissue different from normal tissues will allow the creation of oHSV that act like molecular scalpsels, infecting and removing only the tumorigenic tissues. When designing or using an oHSV, it is important to closely study host virus interactions in order to discover new peculiarities within the tumor that can be exploited by the next generation of vectors. Now that CRISPR/Cas9 and BACs are reliably available, it is faster and easier to create new vectors than ever before. Understanding the cellular factors that antagonize virus replication and spread throughout the tumor, as well as contribute to oncolytic activity will create opportunities to improve oHSV therapy, while the clinical trial results will provide insights into the limitations of oHSV and illuminate pathways to success.

CONFLICT IF INTEREST SDR is a named inventor on patents relating to oncolytic herpes simplex viruses, which were filed by Georgetown University and Massachusetts General Hospital.

ACKNOWLEDGMENTS The authors would like to thank the members of the Brain Tumor Research Center who have contributed to our research. Our studies have been supported in part by grants from the National Institutes of Health (R01CA160762, R01NS032677, and R01CA102139) and the Thomas A. Pappas Chair in Neurosciences.

REFERENCES

1. Russell, SJ, Peng, KW and Bell, JC (2012). Oncolytic virotherapy. Nat Biotechnol 30: 658–670.
2. Roizman, B, Knipe, DM and Whitley, RJ. Herpes simplex viruses. In: Knipe DM and Howley PM (eds). Fields Virology. Lippincott Williams &Wilkins, Philadelphia, 2013. pp 1823–1897.
3. Field, H and Wildy, P (1978). The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J.Virol 30: 267–277.
4. Schubert, A, Gentner, E, Bohn, K, Schwarz, M, Mertens, T and Sauerbrei, A (2014). Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes. Antiviral Res 107: 16–22.
5. Luo, C, Morí, I, Goshima, F, Ushijima, Y, Nawa, A, Kimuma, H et al. (2007). Replication-competent, oncolytic herpes simplex virus type 1 mutants induce a bystander effect following ganciclovir treatment. J Gene Med 9: 875–883.
6. Martuza, RL, Malick, A, Markert, JM, Bufner, RL and Coen, DM (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854–856.
7. Kaplitt, MG, Tjuvajev, JG, Leib, DA, Berk, J, Pettigrew, KD, Posner, JB et al. (1994). Mutant defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. J Neurooncol 44: 131–140.
8. Mineta, T, Rabkin, SD, Yazaki, T, Hunter, WD and Martuza, RL (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1: 938–943.
9. Kanai, A, Zaupa, C, Sgbuin, D, Antoszczyk, SJ, Martuza, RL, Wakimoto, H et al. (2012). Effect of Δ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Clin Virol 56: 256–271.
10. Langelier, Y, Bergeron, S, Chabaud, S, Lippens, J, Guillault, C, Sasseville, AM et al. (2002). The R1 subunit of herpes simplex virus ribonucleotide reductase protects cells against apoptosis at, or upstream of, caspase-8 activation. J Gen Virol 83(Pt 11): 2779–2789.
11. Mineta, T, Rabkin, SD and Martuza, RL (1994). Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex virus mutant. Cancer Res 54: 3963–3966.
12. Nakano, K, Todo, T, Zhao, G, Yamaguchi, K, Kuroki, S, Cohen, JB et al. (2005). Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. J Gene Med 7: 638–643.
13. Walsh, D and Mohr, J (2006). Assembly of an active translation initiation factor complex by a viral protein. Genes Dev 20: 461–472.
14. Wang, X, Li, Y, Liu, S, Yu, X, Li, L, Shi, C et al. (2014). Direct activation of RIP3/MLKL-dependent necrosis by herpes simplex virus 1 (HSV-1) protein ICP6 triggers host antiviral defense. Proc Natl Acad Sci USA 111: 15438–15443.
15. Dehoux, F, Sasseville, AM, Oser, BJ, Chénevaux, B, Siegel, RM and Langelier, Y (2011). The ribonucleotide reductase R1 subunits of herpes simplex virus types 1 and 2 protect cells against TNFα- and FasL-induced apoptosis by interacting with caspase-8. Apoptosis 16: 256–271.
16. He, B, Chou, J, Lieberman, DA, Hoffman, B and Roizman, B (1997). The gamma(1)34.5 protein of herpes simplex virus type 1 complex with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 94: 843–848.
17. Slafera, D, Formenti, SC and Schneider, RJ (2010). Translational control in cancer. Nat Rev Cancer 10: 254–266.
18. He, B, Gross, M and Roizman, B (1997). The gamma134.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 94: 843–848.
19. Aghi, M, Rabkin, SD and Martuza, RL (2009). Hypoxia enhances the replication of Aghi, MK, Liu, TC, Rabkin, S and Martuza, RL (2009). Hypoxia enhances the replication of Aghi, M, Rabkin, S and Martuza, RL (2006). Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Virol 80: 1001–1003.
20. Verpooten, D, Ma, Y, Hou, S, Yan, Z and He, B (2009). Control of TANK-binding kinase 1mediated signaling by the eIF2alpha kinase signaling pathway. Proc Natl Acad Sci USA 99: 190–195.
21. Harland, J, Dunn, P, Cameron, E, Conner, J and Brown, SM (2003). The herpes simplex virus (HSV) protein ICPS4.5 is a virion component that forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication proteins. J Neurovirol 9: 477–488.
22. Wang, Y, Yang, Y, Wu, S, Pan, S, Zhou, C, Ma, Y et al. (2014). P32 is a novel target for ICPS4.5 of herpes simplex virus type 1, and facilitates viral nuclear egress. J Virol 88: 35795–805.
23. Bhutia, SK, Mukhopadhayay, S, Sinha, N, Das, DN, Panda, PK, Patra, SK et al. (2013). Autophagy: cancer's friend or foe? Adv Cancer Res 118: 61–95.

Oncolytic herpes viruses

C Peters and SD Rabbink

Molecular Therapy — Oncolytics (2015) 15010

© 2015 The American Society of Gene & Cell Therapy
39. Orvedahl, A, Alexander, D, Tallozy, Z, Sun, Q, Wei, Y, Zhang, W et al. (2007). HSV-1 ICP34.5 confers neurovirulence by targeting the Bcl-2 autophagy protein. Cell Host Microbe 1: 23–35.

40. Leib, DA, Alexander, DE, Cox, D, Yin, J and Ferguson, TA (2009). Interaction of ICP34.5 with Bcl-2 modulates herpes simplex virus type 1 pathogenesis through control of CD4+ T-cell responses. J Virol 83: 12164–12171.

41. Chernegh, B, Brett, ME and He, B (2002). Signals that dictate nuclear, nucleolar, and cytoplasmic shuttling of the gamma(34.5) protein of herpes simplex virus type 1. J Virol 76: 9434–9445.

42. Chou, J, Kern, ER, Whiteley, RJ and Roizman, B (1990). Mapping of herpes simplex virus type 1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250: 1262–1266.

43. Grovicci, J, Johnson, D and Roizman, B (2002). Cell surface major histocompatibility complex class II proteins are regulated by the product of the gamma(34.5) and UL141 genes of herpes simplex virus 1. J Virol 76: 6974–6986.

44. Leib, DA, Machale, MA, Williams, BR, Silverman, RH and Virgin, HW (2000). Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc Natl Acad Sci USA 97: 6907–6911.

45. Markert, JM, Medlock, MD, Rabkin, SD, Gillespie, GY, Todo, T, Hunter, WD et al. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867–874.

46. Markert, JM, Razdan, SN, Kuo, HC, Cantor, A, Knoll, A, Karrasch, M et al. (2014). A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic response. Mol Thera 22: 1048–1055.

47. Kambara, H, Okano, H, Chiocca, EA and Sawa, Y (2005). An oncolytic HSV-1 mutant expressing IPC34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65: 2832–2839.

48. Kambara, H, Okano, H, Chiocca, EA and Sawa, Y (2005). An oncolytic HSV-1 mutant expressing IPC34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65: 2832–2839.

49. Mohr, I and Gluzman, Y (1996). A herpesvirus gene product which affects translation in the absence of the viral GADD34 function. EMBO J 15: 4759–4766.

50. Mulvey, M, Poppers, J, Ladd, A and Mohr, I (1999). A herpesvirus ribosome-associated, RNA-binding protein confers a growth advantage upon mutants deficient in a GADD34-related function. J Virol 73: 3375–3385.

51. Shah, AC, Parker, JN, Gillespie, GY, Lakeman, FD, Meleth, S, Markert, JM et al. (2012). Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity. J Virol 86: 1262–1266.

52. Taneja, S, MacGregor, J, Markus, S, Ha, S and Mohr, I (2001). Enhanced antitumor efficacy of a US3 inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic tumor therapy. Adv Virus Res 61: 253–265.

53. Gover, N, Waksman, H, Martuza, RL and Rabkin, SD (2007). Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase–Akt targeting molecular therapeutics. Clin Cancer Res 13: 5897–5902.

54. Jiao, Y, Tsuda, S, Liu, Z, Kozuka-Hata, H, Oyama, M and Kawaguchi, Y (2014). Herpes simplex virus 1 protein kinase Us3 phosphorylates viral dUTPase and regulates its catalytic activity in infected cells. J Virol 88: 655–666.

55. Kambara, H, Okano, H, Chiocca, EA and Sawa, Y (2005). An oncolytic HSV-1 mutant expressing IPC34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65: 2832–2839.

56. Mohr, I and Gluzman, Y (1996). A herpesvirus gene product which affects translation in the absence of the viral GADD34 function. EMBO J 15: 4759–4766.

57. Kambara, H, Okano, H, Chiocca, EA and Sawa, Y (2005). An oncolytic HSV-1 mutant expressing IPC34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65: 2832–2839.

58. Taneja, S, MacGregor, J, Markus, S, Ha, S and Mohr, I (2001). Enhanced antitumor efficacy of a herpesvirus protein mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci USA 98: 8004–8008.

59. Cassady, KA, Gross, M and Roizman, B (1998). The herpes simplex virus US11 protein effectively compensates for the gamma 134.5 gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of protein kinase A to block apoptosis. Proc Natl Acad Sci USA 101: 9411–9416.

60. Huard, B and Früh, K (2000). A role for MHC class I down-regulation in NK cell lysis of tumor cells expressing the Herpes simplex virus ICP34.5 conferring neurovirulence upon mutants deficient in a GADD34-related function. J Virol 73: 3375–3385.

61. Shah, AC, Parker, JN, Gillespie, GY, Lakeman, FD, Meleth, S, Markert, JM et al. (2012). Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity. J Virol 86: 1262–1266.
91. Bertrand, L, Leiva-Torres, GA, Hiyazie, H and Pearson, A (2010). Conserved residues in the UL24 protein of herpes simplex virus 1 are important for dispersal of the nucleolar protein nucleocidin. J Virol 84: 109–118.

92. Leiva-Torres, GA, Rochette, PA and Pearson, A (2010). Differential importance of highly conserved residues in UL24 for herpes simplex virus 1 replication in vivo and reactivation. J Gen Virol 91 Pt 7: 1109–1116.

93. Kelly, KL, Hong, J and Fong, Y (2008). Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy. Expert Opin Investig Drugs 17: 1105–1113.

94. Workenhe, ST, Simmons, G, Pol, JG, Lichy, BD, Halford, WP and Mospman, KL (2014). Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol Ther 22: 123–131.

95. Smith, CC (2005). The herpes simplex virus type 2 protein ICP10PK: a master of reactivation. J Biomed Biotechnol 11: 437–445.

96. Aurelian, L (2004). Herpes simplex virus type 2 vaccines: new ground for optimism? Clin Diagn Lab Immunol 11: 437–445.

97. Aurelian, L, Kokuba, H and Smith, CC (1999). Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Vaccine 17: 1951–1963.

98. Morimoto, T, Arii, J, Tanaka, M, Sata, T, Akashi, H, Yamada, M (2001). Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes virus vector to malignant human soft tissue and bone tumors. Cancer Res 61: 3969–3977.

99. Lee, CY, Rennie, PS and Jia, WW (2009). MicroRNA regulation of oncolytic herpes simplex virus 1 for selective killing of prostate cancer cells. Clin Cancer Res 15: 5126–5135.

100. Kuroda, T, Rabkin, SD and Martuza, RL (2006). Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res 66: 10127–10135.

101. Yamamura, H, Hashio, M, Noguchi, M, Sugenoya, Y, Osakada, M, Hirano, N (2007). High-efficiency targeted editing of designed to enter cells solely via the IL-13alpha2 receptor. Mol Ther 15: 12006–12011.

102. Nanni, P, Gatta, V, Menotti, L, De Giovanni, C et al. (2012). Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice. Cancer Gene Ther 19: 788–795.

103. Reisoli, E, Gambini, E, Appolloni, I, Gatta, V, Campadelli-Fiume, G, Menotti, L et al. (2012). Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma. Mol Ther 20: 594–1001.

104. Isolauri, E, Kuroda, T, Martuza, RL and Rabkin, T (2005). Triple gene-deleted oncolytic herpes simplex virus double-armed with interleukin 1b and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res 65: 10663–10668.

105. Reisoli, E, Gambini, E, Appolloni, I, Gatta, V, Barrili, M, Menotti, L et al. (2012). Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice. Cancer Gene Ther 19: 788–795.

106. Kuroda, T, Rabkin, SD and Martuza, RL (2006). Recent advances in the development of oncolytic HSV-1 vectors: ‘arming’ of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction. Curr Opin Mol Ther 9: 447–466.

107. Cheema, TA, Wakimoto, H, Fecci, PE, Nong, J, Kuroda, T, Jeyaretna, D et al. (2013). Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci USA 110: 12006–12011.

108. Argnani, R, Marconi, P, Volpi, I, Bolanos, E, Carro, E, Ried, C et al. (2011). Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer. Liver Int 31: 1542–1553.

109. Yamamoto, S, Deckter, LA, Kasai, K, Chiocca, EA and Saeki, Y (2006). Imaging immediately early and striclate promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors. Gene Ther 13: 1731–1736.

© 2015 The American Society of Gene & Cell Therapy

Molecular Therapy — Oncolytics (2015) 15010

Oncolytic herpes viruses

C Peters and SD Rabbink
Oncolytic herpes viruses
C Peters and SD Rabkin

14. Adusumilli, PS, Stiles, BM, Chan, MK, Eisenberg, DP, Yu, Z, Stanziola, SF et al. (2006). Real-time diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery. *FASEB J* 20: 726–728.

14. Carpenter, S and Fong, Y (2012). Real-time fluorescence imaging of abdominal, pleural, and lymphatic metastases. *Methods Mol Biol* 872: 141–157.

15. Li, H, Nakashima, H, Decklever, TD, Nace, RA and Russell, SJ (2013). HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiotherapy. *Cancer Gene Ther* 20: 478–485.

16. Todo, T, Rabkin, SD and Martuza, RL (2000). Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multumipotent herpes simplex virus type 1 (G207) therapy of brain tumors. *Cancer Gene Ther* 7: 939–946.

17. Nakamura, H, Mulllen, JH, Chandrasekhar, S, Pavlik, TM, Yoon, SS and Tanabe, KK (2001). Multimodality therapy with a replication-conditional herpes simplex virus simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. *Cancer Res* 61: 5447–5452.

18. Goffey, MB, Parker, JN, Luckett, WS Jr, Gillespie, GY, Meleth, S, Whitley, RJ et al. (2007). Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. *Cancer Gene Ther* 14: 45–56.

19. Chase, M, Chung, RY and Chiocca, EA (1998). An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. *Nat Biotechnol* 16: 444–448.

20. Tyminski, E, Leroy, S, Terada, K, Finkelstein, DM, Hyatt, JL, Danks, MK et al. (2005). Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyp2B1 and irinotecan. *Cancer Res* 65: 6850–6857.

21. Braidwood, L, Dunn, PD, Hardy, S, Evans, TR and Brown, SM (2009). Antitumor activity of a selectively replicating competent herpes simplex virus (HSV) with enzyme prodrug therapy. *Anticancer Res* 29: 2159–2166.

22. Bharara, S, Sorcier, EJ, Gillespie, GY, Lindsey, JR, Hong, JS, Curlee, KV et al. (2005). Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy. *Hum Gene Ther* 16: 339–347.

23. Cheema, TA, Kanai, K, Kim, GW, Wakimoto, H, Passer, B, Rabkin, SD et al. (2011). Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. *Clin Cancer Res* 17: 7383–7393.

24. Kulu, Y, Kawasaki, H, Donahue, JM, Kasuya, H, Cusack, JC, Choi, EW et al. (2013). Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis. *Cancer Gene Ther* 20: 133–140.

25. Tamura, K, Wakimoto, H, Agarwal, AS, Rabkin, SD, Bhere, D, Martuza, RL et al. (2013). Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. *Mol Ther* 21: 68–77.

26. Lichty, BD, Breitbach, CJ, Stojdl, DF and Bell, JC (2014). Going viral with cancer immunotherapy. *Nat Rev Cancer* 14: 559–567.

27. Fulci, G, Breymann, L, Gianni, D, Kurozumi, K, Rhee, SS, YU and J et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. *Proc Natl Acad Sci USA* 103: 12873–12878.

28. Alvarez-Brekenridge, CA, Fu, JY, Price, R, Wojton, J, Pradarelli, J, Miao, H et al. (2012). NK cells impede glioblastoma virotherapy through Nkp30 and Nkp46 natural cytotoxicity receptors. *Nat Med* 18: 1822–1834.

29. Toda, M, Rabkin, SD, Kojima, H and Martuza, RL (1999). Herpes simplex virus as an in situ cancer vaccine for the induction of specific antitumor immunity. *Hum Gene Ther* 10: 385–393.

30. Li, H, Dutour, A, Fu, X and Zhang, X (2007). Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. *J Gene Med* 9: 161–169.

31. Varghese, S, Rabkin, SD, Liu, R, Nielsen, PG, Ipe, T and Martuza, RL (2006). Enhanced therapeutic efficacy of il-12, but not GM-CSF, expressing oncolytic simplex virus for transgenic mouse derived prostate cancers. *Cancer Gene Ther* 13: 253–265.

32. Malhotra, S, Kim, T, Zager, J, Bennett, J, Ebright, M, D’Angeliica, M et al. (2007). Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. *Surgery* 141: 520–529.

33. Kaufman, HL, Kim, DW, Deffefele, G, Mitcham, J, Coffin, RS and Kim-Shulze, S (2010). Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. *Ann Surg Oncol* 17: 718–730.

34. Hersey, P and Gallagher, S (2014). Intravenous immunotherapy for melanoma. *J Surg Oncol* 109: 320–326.

35. Lasek, W, Zagoadzson, R and Jakobsen, M (2014). Interleukin 12: still a promising candidate for tumor immunotherapy? *Cancer Immunol Immunother* 63: 419–435.